---
title: "DCOY.US (DCOY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DCOY.US/news.md"
symbol: "DCOY.US"
name: "DCOY.US"
parent: "https://longbridge.com/en/quote/DCOY.US.md"
datetime: "2026-05-21T15:18:52.977Z"
locales:
  - [en](https://longbridge.com/en/quote/DCOY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DCOY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DCOY.US/news.md)
---

# DCOY.US (DCOY.US) — Related News

### [Decoy Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285775006.md)
*2026-05-08T20:50:59.000Z*
### [DCOY Q1'26 Earnings: EPS estimate is (4.12) USD](https://longbridge.com/en/news/285534966.md)
*2026-05-07T11:00:33.000Z*
> DCOY (Decoy Therapeutics Inc.) will announce its Q1'26 earnings on May 14 at 8:00 AM ET. The anticipated EPS is (4.12) U

### [Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston | DCOY Stock News](https://longbridge.com/en/news/284218540.md)
*2026-04-27T04:45:46.000Z*
> Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston | DCOY Stock News

### [Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline | DCOY Stock News](https://longbridge.com/en/news/282197262.md)
*2026-04-09T04:40:49.000Z*
> Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined

### [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://longbridge.com/en/news/281880175.md)
*2026-04-07T12:05:42.000Z*
> In Tuesday's pre-market session, SILO Pharma saw a significant gain of 74.4%, reaching $0.62, while Advanced Biomed rose

### [Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 | DCOY Stock News](https://longbridge.com/en/news/281764122.md)
*2026-04-06T05:15:30.000Z*
> Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 | DCOY S

### [Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split](https://longbridge.com/en/news/281536342.md)
*2026-04-02T13:48:02.000Z*
> Decoy Therapeutics has regained compliance with Nasdaq's minimum bid price requirement after executing a reverse stock s